Nasal Spray Reverses Brain Aging in Aged Mice, Texas A&M Study Finds

Two doses of an experimental nasal spray rolled back markers of brain aging in 18-month-old mice, the rough equivalent of a 60-year-old human, according to a Texas A&M University study published in the Journal of Extracellular Vesicles. The therapy uses microscopic packages called extracellular vesicles, harvested from human stem cells and loaded with two specific microRNAs, that travel directly into brain tissue through the nose. Two doses produced effects that lasted for months, the team reported.

The result drew breathless coverage this month under headlines about reversed aging. Less reported is what made the delivery work in the first place. Intranasal extracellular vesicle therapy is starting to look less like an experimental trick and more like a fledgling drug class, with multiple labs converging on the same route into the brain.

Inside the Texas A&M Study Design

The work was led by Ashok Shetty, a university distinguished professor and associate director at Texas A&M’s Institute for Regenerative Medicine, with senior research scientists Madhu Leelavathi Narayana and Maheedhar Kodali. Their paper, “Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus,” appeared in 2026 in the Journal of Extracellular Vesicles peer-reviewed study record.

The team treated late middle-aged C57BL/6J mice, both male and female, at 18 months old. Two intranasal doses were administered, and the animals were assessed at 20.5 months. Control animals received no treatment. Behavioral assessments included tasks that gauge memory for objects and awareness of where things sit in space, the kind of recognition work that flags early cognitive slippage in rodents.

A simple framing helps here. Researchers harvested the spray’s active ingredient from human induced pluripotent stem cells (hiPSCs, adult cells reprogrammed back to an embryonic-like state) that had then been pushed to become neural stem cells (NSCs). Those NSCs naturally shed nanoscale bubbles, the extracellular vesicles, as part of normal cellular communication. The lab collected the vesicles, characterized their cargo, and packaged the result for nasal delivery.

“The mode of delivery is one of the most exciting aspects of our approach,” Kodali said in the university’s own announcement of the findings. “Intranasal delivery allows us to reach, and treat, the brain directly without invasive procedures.”

How the Nasal Spray Crosses the Blood-Brain Barrier

The blood-brain barrier (BBB, a tight lattice of endothelial cells that lines brain blood vessels) is why neurology has been a notoriously brutal field for drug developers. Roughly 98% of small-molecule drugs fail to cross it. Almost no large-molecule biologics get through at all. That single bottleneck explains why so many Alzheimer’s compounds that look promising in a dish never reach patients with meaningful effect.

Nasal delivery sidesteps the barrier altogether. Olfactory nerves run from the upper nasal cavity directly into the brain, providing a short physical path that bypasses systemic circulation. Trigeminal nerves offer a second route. Particles small enough to traverse those nerve sheaths, or to ride the cerebrospinal fluid that bathes them, can reach brain tissue within minutes of a spray.

That is why extracellular vesicles work well in this context. Each vesicle is a membrane sphere, typically 30 to 150 nanometers across, smaller than most viruses. They are biological by origin, so the brain’s immune cells generally treat them as native traffic rather than as a foreign object to clear.

Once inside the aged mouse brain, the Texas A&M vesicles homed to microglia and astrocytes, the resident immune cells. Those cells become chronically activated with age, locked into a low-grade inflammatory state researchers now call neuroinflammaging. Calming them, the team argued, is the lever that flips most of the downstream improvements.

The Two MicroRNAs Doing the Heavy Lifting

Drugmakers have been chasing inflammation in the aging brain for two decades. The Texas A&M paper narrows the target further: two specific microRNAs (miRNAs, short non-coding RNA strands that switch genes on and off) carried inside each vesicle.

The team identified the active payloads by elimination. They engineered vesicles with key miRNAs depleted, then re-ran the experiment. The pattern that emerged is clean. miR-30e-3p shuts down one inflammatory alarm; miR-181a-5p shuts down a second.

NLRP3 (NOD-like receptor protein 3) and cGAS-STING (cyclic GMP-AMP synthase, stimulator of interferon genes) are two of the most studied inflammation pathways in age-related disease. They normally fire when cells detect damage or pathogen DNA. In aged tissue, they fire constantly, even without an obvious trigger, releasing signals that exhaust nearby neurons.

A separately published study, indexed in the NIH miR-181a-5p neural stem cell research record, found that the same microRNA, when overexpressed in the hippocampus, enhances neural stem cell proliferation and improves memory in aged mice. The new result lines up with that earlier finding, this time delivered by spray rather than viral injection.

“MicroRNAs act like master regulators,” Narayana said. “They help modulate and regulate many gene and signaling pathways in the brain.”

Memory Tests and Mitochondrial Recovery

The behavioral data is where the headline came from. Treated mice outperformed untreated controls across recognition tasks, identifying familiar objects, noticing novel ones, and registering changes in their surroundings.

On the cellular side, the hippocampus of treated animals looked materially different from the controls:

• Reduced microglial clustering in the hippocampus, the brain region most associated with memory formation
• Lower astrocyte hypertrophy, a long-running signature of brain inflammation
• Elevated levels of antioxidant proteins in hippocampal tissue
• Restored mitochondrial activity in neurons, measured through cellular energy markers

The mitochondrial finding matters because energy is upstream of almost every neuronal job. Mitochondria are the structures inside cells that produce ATP, the chemical fuel everything else burns. Aging and inflammation damage them. Damaged mitochondria release reactive oxygen species, which further inflame the surrounding cells, which further damage the mitochondria. That loop is one of the field’s hardest to break.

“We are giving neurons their spark back by reducing oxidative stress and reactivating the brain’s mitochondria,” Narayana said.

The effects persisted for months after only the two doses, the team reported. That durability is unusual for an inflammatory intervention. Most anti-inflammatory drugs require continuous dosing because the pathways they target snap back as soon as the drug clears. The proposed explanation is that the spray flips microglia out of their chronic activation state into something closer to a resting profile, and the state holds because the upstream triggers were also tamped down. Sex differences barely showed up; male and female animals responded similarly, a result the team called “universal.”

A Wider Wave of Intranasal Brain Therapies

Intranasal drug delivery is not new. Sumatriptan sprays for migraine have been on the market for decades. What has changed in the last five years is the cargo. Researchers are now using the nasal route to ferry molecules far larger and far more fragile than small-molecule painkillers: peptides, exosomes, and now stem-cell-derived vesicles.

The Wake Forest School of Medicine ran the SNIFF trial, an intranasal insulin study testing whether bypassing the BBB could deliver enough insulin to slow Alzheimer’s progression. Other labs have explored intranasal oxytocin for social cognition disorders and intranasal IGF-1 (insulin-like growth factor 1) for stroke recovery. None has produced a clinical home run yet, but the pattern is unmistakable. When a brain target is otherwise unreachable, the nose has become the field’s preferred workaround.

Extracellular vesicle therapy adds something the other intranasal programs lack, which is a payload the brain treats as familiar rather than foreign. Synthetic nanoparticles can lodge in tissues and trigger their own immune response. Cell-derived vesicles, in theory, slip through with less collateral noise.

The market follows the science. The global extracellular vesicle therapeutics segment is forecast to grow from under $50 million in 2023 into the multi-billion range by the early 2030s, driven by programs in neurology, oncology, and orthopedics. The Texas A&M filing of a U.S. patent on the nasal-spray formulation positions the university squarely inside that race.

The Gap Between Aged Mice and Aging Humans

For all the encouraging biology, the gap from this paper to a human therapy is the same gap most preclinical neuroscience never closes. Mouse models of aging do not capture the heterogeneity of human cognitive decline. An 18-month-old C57BL/6 mouse shows some markers of brain aging, but it does not carry decades-long amyloid plaques, mixed dementia pathologies, or the cardiovascular comorbidities that complicate any human trial.

The therapy is also a biological product, not a chemical one. Manufacturing extracellular vesicles at clinical scale, with batch-to-batch consistency, is a substantially harder problem than synthesizing a small molecule. The hiPSC-NSC source adds another layer of regulatory complexity, since the U.S. Food and Drug Administration scrutinizes cell-derived products more closely than synthetic drugs.

Although more research is needed before the treatment could be tested in humans, the study offers a striking possibility: brain aging may not simply be an unavoidable part of getting older.

Shetty himself framed the patent filing as a translation step, not a clinical promise. “We aren’t just trying to understand the biological mechanisms, we are translating and developing our findings into real-world therapies that could make a difference,” he said. The work is supported by the National Institute on Aging’s program funding, and a phase-one safety trial would be the next major milestone after additional preclinical packages.

The macro context is what gives the result urgency. Annual U.S. dementia cases are projected to roughly double, from about 514,000 in 2020 to 1 million by 2060, according to the Alzheimer’s Association facts and figures report. Even a partial therapeutic win against neuroinflammaging would reshape that curve.

If the next preclinical packages hold up and a first human trial clears safety, intranasal vesicle therapy moves from a single paper into a recognized clinical category. If the manufacturing scales prove brittle or the human aging brain proves stubborner than the mouse one, this becomes one more promising rodent result whose memory the field carefully preserves.

Frequently Asked Questions

What Is the Texas A&M Nasal Spray Made Of?

The spray contains extracellular vesicles, nanoscale membrane bubbles released by human induced pluripotent stem cell-derived neural stem cells. Each vesicle carries microRNAs, with miR-30e-3p and miR-181a-5p identified as the two key payloads that suppress inflammatory signalling in the aged brain.

Has the Therapy Been Tested in Humans?

No. The published results come exclusively from late middle-aged mice. A U.S. patent has been filed, but human safety trials would require additional preclinical work plus regulatory clearance before any first-in-human study can begin.

How Does a Nasal Spray Reach the Brain?

The olfactory and trigeminal nerves connect the upper nasal cavity directly to brain tissue, bypassing the blood-brain barrier that blocks roughly 98% of small-molecule drugs. Particles small enough to traverse those nerve pathways can reach brain tissue within minutes.

What Is Neuroinflammaging?

Neuroinflammaging is the chronic, low-grade inflammation in brain tissue that accumulates with age. It is driven by overactive microglia and astrocytes and is considered a major contributor to dementia, Alzheimer’s disease, and broader cognitive decline.

Could This Treat Alzheimer’s or Dementia?

The team’s framing is that age-related cognitive decline and dementia share inflammatory drivers, so a therapy that quiets those drivers could in principle benefit both. The published evidence does not yet show effect on Alzheimer’s-specific pathologies like amyloid plaques or tau tangles in any animal model.

Who Funded the Research?

Funding came from the National Institute on Aging. Texas A&M’s Institute for Regenerative Medicine led the work, and the university has filed a U.S. patent on the nasal-spray formulation.

When Could a Clinical Trial Begin?

The team has not announced a date. Typical translation timelines from a published rodent result to a first human dose run three to seven years, depending on manufacturing complexity, additional preclinical safety packages, and regulatory pathway.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. The therapy described is experimental and has been tested only in mice; it is not available to patients. Readers with questions about cognitive health, dementia risk, or experimental treatments should consult a qualified neurologist or physician. Figures are accurate as of publication.